Point of Care (POC) Diagnostics Market By Type (Glucose Monitoring Products (Strips, Lancets & Lancing Devices, and Meters), Cardiometabolic Monitoring Products (Cardiac Marker Testing Products, Hba1c Testing Products, and Blood Gas/Electrolyte Testing Products), Infectious Disease Testing Products (Influenza Testing Products, Hepatitis C Testing Products, HIV Testing Products, Healthcare-Associated Infection Testing Products, Sexually Transmitted Disease Testing Products, and Others), Coagulation Monitoring Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, and Others), By End Users (Hospitals/Critical Care Centers, Diagnostic Centers, Research Laboratories, Home Care Settings, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Point-of-care (POC) testing allows physicians and medical staff to provide immediate, convenient, and easy-to-use diagnostic testing that shortens the therapeutic time when providing care for a patient. Point-of-care testing helps to make rapid treatment decisions when diagnosing a patient’s condition or monitoring treatment response. Point-of-care testing is done in a healthcare organization and homecare setting.

Point of Care (POC) Diagnostics market was valued at 19 billion US$ in 2022 and is projected to reach 32.2 billion US$ by 2030, at a CAGR of 6.8% during the forecast period.

Market Dynamics

Rising prevalence of infectious diseases are key driving factors of the global point of care (POC) diagnostics market. Infectious diseases include tuberculosis, hepatitis B, hepatitis C, HIV/AIDS, Chagas disease, diarrheal diseases, and other infectious diseases. According to the World Health Organization (WHO), more than 10 million people fell ill with tuberculosis (TB) worldwide in 2018, including 5.7 million men, 3.2 million women, and 1.1 million children. According to the U.S. Department of Health & Human Services, approximately 37.9 million people had HIV/AIDS in 2018, of which 1.7 million were children (<15 years old) and 36.2 million were adults. In 2018, 1.7 million people newly infected with HIV. According to the Hepatitis B Foundation, approximately 2 billion people have been infected with the hepatitis B virus, and 30 million people become newly infected each year. Around 884,000 people die each year from hepatitis B. According to the World Health Organization (WHO), as of 2019, 71 million people have chronic hepatitis C virus infection. According to the Centers for Disease Control and Prevention, more than 300,000 persons with Chagas disease live in the United States. About 8 million people are infected with Chagas disease in Mexico, Central America, and South America. According to the World Health Organization (WHO), globally, there are around 1.7 billion cases of childhood diarrhoeal disease every year. Point of Care Tests helps to detect various infectious diseases related to biomarkers, including nucleic acids, proteins, virus particles, and antibodies. However, high procedure costs of POC devices coupled with limited adoption in emerging regions, product recalls, and stringent approval policies might hamper the market growth. Moreover, government initiative and funding for point of care (POC) testing would provide lucrative opportunities for the market in the coming years. Market Segmentation

The global point of care (POC) diagnostics market is mainly classified based on type and end-users. Type is further segmented into Glucose Monitoring Products, Cardiometabolic Monitoring Products, Infectious Disease Testing Products, Coagulation Monitoring Products, Pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, and Others. By end-users, the market is divided into Hospitals/Critical Care Centers, Diagnostic Centers, Research Laboratories, Home Care Settings, and Others.

Infectious disease testing products are expected to dominate the point of care (POC) diagnostics market in 2022. The increasing need of point-of-care (POC) testing for the detection of novel coronavirus (COVID-19) and the Emergency Use Authorization (EUA) by regulatory bodies for point of care (POC) testing to detect novel coronavirus (COVID-19) are some of the factors boosting the global point of care (POC) diagnostics market. For instance, it has received the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in five minutes and negative results in 13 minutes. The point-of-care test will run on the company’s ID NOW platform, providing results in a wide range of healthcare settings such as urgent care clinics and hospital emergency departments.

Regional Analysis

Based on geography, the global point of care (POC) diagnostics market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global point of care (POC) diagnostics market in 2019, due to the rising prevalence of infectious diseases in this region, regulatory approval of point of care (POC) products, and commercialization of advanced and new regulatory approved products. For instance, Abbott has introduced Afinion HbA1c Dx assay for use on the Afinion 2 Analyzer and the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to diagnose diabetes and the assessment of patients’ risk of developing the condition. Moreover, the regulatory bodies are funding companies to develop a point of care testing for COVID-19 is boosting the North America point of care (POC) diagnostics market. For instance, the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA), has funded $13 million to Cue Health. The company aims to develop a handheld molecular point-of-care device that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19.

Competitive landscape

Key players operating in the point of care (POC) diagnostics industry include Abbott Laboratories, Becton, Dickinson, and Company, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Chembio Diagnostics, Danaher Corporation, Siemens Healthineers, Quidel, Trinity Biotech, EKF Diagnostics, Accubiotech, Nova Biomedical, Instrumentation Laboratory, Sekisui Diagnostics, and PTS Diagnostics.

The partnership between companies to develop and distribute the products and expand their presence in global market, regulatory approval of point of care testing products, raising funds to develop a point of care testing products, and commercialization of advanced and new regulatory approved products are some of the strategies adopted by the companies. For instance, Mindray Medical has introduced the TE7 ACE point-of-care ultrasound system to provide targeted solutions in various point-of-care scenarios, such as critical care, anesthesia, and emergency. The touchscreen ultrasound system comprises a disinfection solution, safe needling toolkit and smart fluid management tools, and offering seamless data connectivity.

Point of Care (POC) Diagnostics Market Key Segments

By Type
• Glucose Monitoring Products
o Strips
o Meters
o Lancets & Lancing Devices
• Cardiometabolic Monitoring Products
o Cardiac Marker Testing Products
o Blood Gas/Electrolyte Testing Products
o Hba1c Testing Products
• Infectious Disease Testing Products
o Influenza Testing Products
o HIV Testing Products
o Hepatitis C Testing Products
o Sexually Transmitted Disease Testing Products
o Healthcare-Associated Infection Testing Products
o Others
• Coagulation Monitoring Products
• Pregnancy & Fertility Testing Products
• Tumor/Cancer Marker Testing Products
• Urinalysis Testing Products
• Cholesterol Testing Products
• Hematology Testing Products
• Others

By End Users
• Hospitals/Critical Care Centers
• Diagnostic Centers
• Research Laboratories
• Home Care Settings
• Others

Key Global Point of Care (POC) Diagnostics Industry Players

• Abbott Laboratories
• Becton, Dickinson, and Company
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Chembio Diagnostics
• Danaher Corporation
• Siemens Healthineers
• Quidel
• Trinity Biotech
• EKF Diagnostics
• Accubiotech
• Nova Biomedical
• Instrumentation Laboratory
• Sekisui Diagnostics
• PTS Diagnostics

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Point of Care (POC) Diagnostics Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence of Infectious Diseases
3.4. Restraints
3.4.1. High Procedure Costs of POC Devices Coupled with Limited Adoption in Emerging Regions
3.4.2. Product Recalls
3.5. Opportunity
3.5.1. Government Initiative and Funding for Point of Care (POC) Testing
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Glucose Monitoring Products
4.2.1. Market Size & Forecast
4.2.1.1. Strips
4.2.1.2. Meters
4.2.1.3. Lancets & Lancing Devices
4.3. Cardiometabolic Monitoring Products
4.3.1. Market Size & Forecast
4.3.1.1. Cardiac Marker Testing Products
4.3.1.2. Blood Gas/Electrolyte Testing Products
4.3.1.3. Hba1c Testing Products
4.4. Infectious Disease Testing Products
4.4.1. Market Size & Forecast
4.4.1.1. Influenza Testing Products
4.4.1.2. HIV Testing Products
4.4.1.3. Hepatitis C Testing Products
4.4.1.4. Sexually Transmitted Disease Testing Products
4.4.1.5. Healthcare-Associated Infection Testing Products
4.4.1.6. Others
4.5. Coagulation Monitoring Products
4.5.1. Market Size & Forecast
4.6. Pregnancy & Fertility Testing Products
4.6.1. Market Size & Forecast
4.7. Tumor/Cancer Marker Testing Products
4.7.1. Market Size & Forecast
4.8. Urinalysis Testing Products
4.8.1. Market Size & Forecast
4.9. Cholesterol Testing Products
4.9.1. Market Size & Forecast
4.10. Hematology Testing Products
4.10.1. Market Size & Forecast
4.11. Others
4.11.1. Market Size & Forecast

5. End Users Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hospitals/Critical Care Centers
5.2.1. Market Size & Forecast
5.3. Diagnostic Centers
5.3.1. Market Size & Forecast
5.4. Research Laboratories
5.4.1. Market Size & Forecast
5.5. Home Care Settings
5.5.1. Market Size & Forecast
5.6. Others
5.6.1. Market Size & Forecast

6. Point of Care (POC) Diagnostics Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Point of Care (POC) Diagnostics Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By End Users
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Point of Care (POC) Diagnostics Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By End Users
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Point of Care (POC) Diagnostics Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By End Users
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Point of Care (POC) Diagnostics Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By End Users
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Point of Care (POC) Diagnostics Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By End Users
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Abbott Laboratories
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Abbott Laboratories Product Category, Application, and Specification
7.1.3. Abbott Laboratories Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Becton, Dickinson, and Company
7.3. Johnson & Johnson
7.4. F. Hoffmann-La Roche Ltd.
7.5. Chembio Diagnostics
7.6. Danaher Corporation
7.7. Siemens Healthineers
7.8. Quidel
7.9. Trinity Biotech
7.10. EKF Diagnostics
7.11. Accubiotech
7.12. Nova Biomedical
7.13. Instrumentation Laboratory
7.14. Sekisui Diagnostics
7.15. PTS Diagnostics